User login
Key clinical point: Ustekinumab induced and maintained steroid-free clinical remission to 1 year in a significant proportion of children with extensive and treatment-refractory ulcerative colitis (UC).
Major finding: At week 52, 44% of children who received ustekinumab achieved steroid-free remission. This included 69% of those previously treated with antitumor necrosis factor (anti-TNF) only vs. 17% of those who previously failed vedolizumab (P = .008). No adverse events were reported.
Study details: Data come from an open-label prospective cohort study of 25 children with anti-TNF refractory UC who were treated with intravenous ustekinumab. All patients had failed prior infliximab therapy, whereas 12 patients also failed vedolizumab.
Disclosures: The study was funded by the Canadian Institutes of Health Research and Children's Intestinal and Liver Disease Foundation. Some of the authors reported serving as a consultant, speaker, advisory board member for and receiving speaker/consultation fees, honoraria, and/or research support from multiple sources.
Source: Dhaliwal J et al. Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
Key clinical point: Ustekinumab induced and maintained steroid-free clinical remission to 1 year in a significant proportion of children with extensive and treatment-refractory ulcerative colitis (UC).
Major finding: At week 52, 44% of children who received ustekinumab achieved steroid-free remission. This included 69% of those previously treated with antitumor necrosis factor (anti-TNF) only vs. 17% of those who previously failed vedolizumab (P = .008). No adverse events were reported.
Study details: Data come from an open-label prospective cohort study of 25 children with anti-TNF refractory UC who were treated with intravenous ustekinumab. All patients had failed prior infliximab therapy, whereas 12 patients also failed vedolizumab.
Disclosures: The study was funded by the Canadian Institutes of Health Research and Children's Intestinal and Liver Disease Foundation. Some of the authors reported serving as a consultant, speaker, advisory board member for and receiving speaker/consultation fees, honoraria, and/or research support from multiple sources.
Source: Dhaliwal J et al. Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
Key clinical point: Ustekinumab induced and maintained steroid-free clinical remission to 1 year in a significant proportion of children with extensive and treatment-refractory ulcerative colitis (UC).
Major finding: At week 52, 44% of children who received ustekinumab achieved steroid-free remission. This included 69% of those previously treated with antitumor necrosis factor (anti-TNF) only vs. 17% of those who previously failed vedolizumab (P = .008). No adverse events were reported.
Study details: Data come from an open-label prospective cohort study of 25 children with anti-TNF refractory UC who were treated with intravenous ustekinumab. All patients had failed prior infliximab therapy, whereas 12 patients also failed vedolizumab.
Disclosures: The study was funded by the Canadian Institutes of Health Research and Children's Intestinal and Liver Disease Foundation. Some of the authors reported serving as a consultant, speaker, advisory board member for and receiving speaker/consultation fees, honoraria, and/or research support from multiple sources.
Source: Dhaliwal J et al. Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.